(Q28171051)

7

object named as

S Visvikis

0 references

author name string

G Siest

1

0 references

E Jeannesson

2

0 references

H Berrahmoune

3

0 references

S Maumus

4

0 references

J-B Marteau

5

0 references

S Mohr

Pharmacogenomics of Drugs Affecting the Cardiovascular System

6

0 references

language of work or name

English

0 references

publication date

October 2004

0 references

published in

Pharmacogenomics

0 references

volume

5

0 references

issue

7

0 references

page(s)

779-802

0 references

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Pharmacogenomics: translating functional genomics into rational therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Cytochrome P450 enzyme polymorphisms and adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Pharmacogenetics of warfarin elimination and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Clinical pharmacokinetics of cerivastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Cytochrome P450 3A and their regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Implications of pharmacogenetics for individualizing drug treatment and for study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Pharmacogenetics of soluble sulfotransferases (SULTs)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Drug interactions: Proteins, pumps, and P-450s

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Are we ready for pharmacogenomics in heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

The emerging role of pharmacogenomics in the treatment of patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Pharmacogenetics goes genomic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

The pathogenesis of coronary artery disease and the acute coronary syndromes (1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Antiplatelet agents in the prevention and therapy of thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Family studies: their role in the evaluation of genetic cardiovascular risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Platelet glycoprotein IIIa polymorphism and coronary thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

PlA2 polymorphism and efficacy of aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Platelet glycoprotein IIIa Pl(a) polymorphism, fibrinogen, and platelet aggregability: The Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Pharmacogenomics of diuretic drugs: data on rare monogenic disorders and on polymorphisms and requirements for further research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Pharmacogenetics and drug-induced arrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Pharmacogenomics of congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Pharmacogenomics of primary hypertension--the lessons from the past to look toward the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Pharmacogenomics of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Banting lecture 1988. Role of insulin resistance in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Genetic mapping and tailored antihypertensive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Pharmacogenetic evidence that cd36 is a key determinant of the metabolic effects of pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Pharmacogenetics of Lipid-lowering Therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Apolipoprotein E polymorphisms and concentration in chronic diseases and drug responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Interethnic variation of drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Pharmacogenomics: the inherited basis for interindividual differences in drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Pharmacogenetics, pharmacogenomics, and pharmacobiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Apolipoprotein E polymorphism in a Danish population compared to findings in 45 other study populations around the world

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Cardiovascular pharmacology of aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Gender-specific implications for cardiovascular medication use in the elderly optimizing therapy for older women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Race and sex influence clearance of nifedipine: results of a population study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

The influence of sex on pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Beta(2)-adrenergic receptor gene polymorphism, age, and cardiovascular phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Polymorphisms in CYP-7A1, not APOE, influence the change in plasma lipids in response to population dietary change in an 8 year follow-up; results from the Czech MONICA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

The APOE locus and the pharmacogenetics of lipid response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Cigarette smoking and clinically significant drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Synergistic effect of apolipoprotein E polymorphisms and cigarette smoking on risk of ischemic stroke in young adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Influence of apolipoprotein E, smoking, and alcohol intake on carotid atherosclerosis: National Heart, Lung, and Blood Institute Family Heart Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Cardiovascular pharmacogenetics in the SNP era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Cardiovascular pharmacogenomics: current status, future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: the way forward

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Common variations in platelet glycoproteins: pharmacogenomic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Molecular basis of cardiovascular drug metabolism: implications for predicting clinically important drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Pharmacogenetics of the major polymorphic metabolizing enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

The Pl(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Increased Platelet Aggregability Associated With Platelet GPIIIa Pl A2 Polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Objectives, Design and Recruitment of a Familial and Longitudinal Cohort for Studying Gene-Environment Interactions in the Field of Cardiovascular Risk: The Stanislas Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779

Genome scans and candidate gene approaches in the study of common diseases and variable drug responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.5.7.779